CD27/TNFRSF7 Antibody (BLR083G)

Western Blot: CD27/TNFRSF7 Antibody (BLR083G) [NBP2-78837] - Detection of human CD27 by WB of HeLa, Ramos, HEK293T, Raji, Jurkat, K-562, U2OS, Daudi, MCF-7, and CCRF-CEM lysate. Antibody: Rabbit anti-CD27 recombinant monoclonal [BLR083G] (NBP2-78837). Secondary: HRP-conjugated goat anti-rabbit IgG. Lower Panel: Rabbit anti-GAPDH.

Immunocytochemistry: CD27/TNFRSF7 Antibody (BLR083G) [NBP2-78837] - Detection of human CD27 in FFPE Ramos cells by ICC. Antibody: Rabbit anti-CD27 recombinant monoclonal antibody [BLR083G] (NBP2-78837). Secondary: HRP-conjugated goat anti-rabbit IgG. Substrate: DAB.

Immunohistochemistry-Paraffin: CD27/TNFRSF7 Antibody (BLR083G) [NBP2-78837] - Detection of human CD27 in FFPE tonsil by IHC. Antibody: Rabbit anti-CD27 recombinant monoclonal antibody [BLR083G] (NBP2-78837). Secondary: HRP-conjugated goat anti-rabbit IgG. Substrate: DAB.

Immunoprecipitation: CD27/TNFRSF7 Antibody (BLR083G) [NBP2-78837] - Detection of human CD27 by WB of immunoprecipitates from Ramos lysate. Antibodies: Rabbit anti-CD27 recombinant monoclonal [BLR083G] (NBP2-78837) and another rabbit anti-CD27.

• Reactivity: Hu
• Applications: WB, Flow, ICC/IF, IHC, IP
• Clone: BLR083G
• Clonality: Monoclonal
• Host: Rabbit
• Conjugate: Unconjugated
• Concentration: This product is unpurified. The exact concentration of antibody is not quantifiable.

CD27/TNFRSF7 Antibody (BLR083G) Summary

• Description: Novus Biologicals Rabbit CD27/TNFRSF7 Antibody (BLR083G) (NBP2-78837) is a recombinant monoclonal antibody validated for use in IHC, WB, Flow, ICC/IF and IP. All Novus Biologicals antibodies are covered by our 100% guarantee.
• Additional Information: Recombinant Monoclonal Antibody
• Immunogen: Immunogen was a recombinant protein representing the extracellular domain of human CD27 (residues 21-187, NP_001233.1).
• Clonality: Monoclonal
• Host: Rabbit
• Gene: CD27
• Purity: Tissue culture supernatant

Applications/Dilutions

• Dilutions:
  • Flow Cytometry
  • Immunocytochemistry/ Immunofluorescence 1:100 - 1:500
  • Immunohistochemistry 1:100 - 1:500
  • Immunohistochemistry-Paraffin
  • Immunoprecipitation 20 ul/1 mg lysate
  • Western Blot 1:1000
• Application Notes: Epitope retrieval with citrate buffer pH6.0 is recommended for FFPE cell sections.

Packaging, Storage & Formulations

• Storage: Store at 2 - 8 C / 1 year from date of receipt
• Buffer: Borate Buffered Saline (BBS) (pH 8.2), 0.1% BSA
• Preservative: 0.09% Sodium Azide
• Concentration: This product is unpurified. The exact concentration of antibody is not quantifiable.
• Purity: Tissue culture supernatant

Notes

This Product sold under License from Bethyl Laboratories, Inc.

Alternate Names for CD27/TNFRSF7 Antibody (BLR083G)

• CD27 antigen
• CD27 molecule
• CD27
• MGC20393
• S152CD27L receptor
• T cell activation antigen CD27
• T cell activation antigen S152
• T14
• TNFRSF7
• TNFRSF7T-cell activation antigen CD27
• Tp55
• Tumor necrosis factor receptor superfamily member 7
• tumor necrosis factor receptor superfamily, member 7

Background

CD27, also referred to as tumor necrosis factor receptor superfamily, member 7 (TNFRSF7), is a type I transmembrane glycoprotein that functions as a co-stimulatory T cell receptor and is expressed on the surface of T cells, natural killer (NK) cells, and B cells (1,2). The human CD27 protein is 260 amino acids (aa) in length and consists of a 19 aa signal sequence, 172 aa extracellular domain (ECD) containing three characteristic cysteine-rich domains (CRDs), a 21 aa helical transmembrane region, and a 48 aa cytoplasmic tail domain (3,4). The CD27 protein has a theoretical molecular weight (MW) of 29 kDa, but is typically is closer to 50-55 kDa due to N-linked and O-linked glycosylation (3). Mouse CD27 cDNA encodes a 250 aa protein with a theoretical molecular weight of 28 kDa (5). Human CD27 shares ~64% aa sequence identity with mouse CD27 protein.

Membrane-bound CD27 is expressed as a disulfide-linked homodimer (3). CD27 binds to the ligand CD70, a transmembrane glycoprotein that is transiently expressed on activated immune cells such as antigen presenting cells (APCs), dendritic cells (DCs), NK cells, B cells, and T cells (1,2,6,7). The receptor-ligand binding interaction leads to NFkappaB and c-Jun pathway activation which promotes immune stimulation and activation and survival of CD4+ T cells, CD8+ T cells, memory T cells, and NK cells (2,6,7). Both CD27 and CD70 are often abnormally expressed or dysregulated on malignant and cancer cells leading to immune evasion and tumor progression (7). CD27 has become a target of interest of immunotherapies for viral infections, autoimmune disease, and cancer (2). Varlilumab, an agonistic CD27 monoclonal antibody (mAB), has entered clinical trials for the treatment of hematological and solid tumor cancers (1,6). Additional clinical trials are in process that combine varlilumab with other immune checkpoint inhibitors like the programmed cell death protein-1 (PD-1) blocking mAb nivolumab (1,2). Initial results are promising, suggesting that targeting CD27, especially in combination with other therapeutics, may be a promising and effective immunotherapy for a variety of pathologies (1,2,6).

References

1. Starzer AM, Berghoff AS. New emerging targets in cancer immunotherapy: CD27 (TNFRSF7). ESMO Open. 2020;4(Suppl 3):e000629. https://doi.org/10.1136/esmoopen-2019-000629

2. Grant EJ, Nussing S, Sant S, Clemens EB, Kedzierska K. The role of CD27 in anti-viral T-cell immunity. Curr Opin Virol. 2017;22:77-88. https://doi.org/10.1016/j.coviro.2016.12.001

3. Buchan SL, Rogel A, Al-Shamkhani A. The immunobiology of CD27 and OX40 and their potential as targets for cancer immunotherapy. Blood. 2018;131(1):39-48. https://10.1182/blood-2017-07-741025

4. Uniprot (P26842)

5. Uniprot (P41272)

6. van de Ven K, Borst J. Targeting the T-cell co-stimulatory CD27/CD70 pathway in cancer immunotherapy: rationale and potential. Immunotherapy. 2015;7(6):655-667. https://doi.org/10.2217/imt.15.32

7. Flieswasser T, Van den Eynde A, Van Audenaerde J, et al. The CD70-CD27 axis in oncology: the new kids on the block. J Exp Clin Cancer Res. 2022;41(1):12. https://doi.org/10.1186/s13046-021-02215-y

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Gene Symbol: CD27